The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

RFK Jr. is making good on his promise to radically reshape the vaccine policy landscape as he ousts the entire CDC Advisory ...

Moderna MRNA announced the FDA approval for mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, though for a ...

Unpredictable and politically driven regulatory approaches cultivate an environment of enormous uncertainty for vaccine ...

The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by rising vaccine uptake, impr ...

Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.

Mount Etna has again captivated the world with a spectacular show.

US growth likely to slow to 1.6% this year, hobbled by Trump's trade wars, OECD says. U.S. economic growth will slow to 1.6% this year from 2.8% last year as President ...

Authorities investigate after 8 injured in Colorado attack by man they say yelled 'Free Palestine' ...

The FDA may be facing a 4% cut to its overall budget courtesy of the Trump administration, but that hasn’t stopped the agency ...